PCTH: a novel orally active chelator for the treatment of iron overload disease (Q36422479)

14 August 2017

1 reference

title

PCTH: a novel orally active chelator for the treatment of iron overload disease (English)

1 reference

14 August 2017

1 reference

David B Lovejoy

1

1 reference

14 August 2017

Danuta Kalinowski

series ordinal

2

1 reference

14 August 2017

Paul V Bernhardt

series ordinal

3

1 reference

14 August 2017

Des R Richardson

series ordinal

4

1 reference

14 August 2017

language of work or name

1 reference

1 January 2006

1 reference

14 August 2017

1 reference

14 August 2017

volume

30

1 reference

14 August 2017

issue

1

1 reference

14 August 2017

page(s)

93-104

1 reference

Iron chelators for the treatment of iron overload disease: relationship between structure, redox activity, and toxicity.

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F03630260500455367

The evolution of iron chelators for the treatment of iron overload disease and cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03630260500455367

Beta-thalassaemia: emergence of new and improved iron chelators for treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03630260500455367

Molecular pathogenesis of Friedreich ataxia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03630260500455367

Recent advances in the molecular pathogenesis of Friedreich ataxia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03630260500455367

Friedreich's ataxia: iron chelators that target the mitochondrion as a therapeutic strategy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03630260500455367

Iron trafficking in the mitochondrion: novel pathways revealed by disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03630260500455367

The design and development of deferiprone (L1) and other iron chelators for clinical use: targeting methods and application prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03630260500455367

Development of novel aroylhydrazone ligands for iron chelation therapy: 2-pyridylcarboxaldehyde isonicotinoyl hydrazone analogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03630260500455367

A study of intracellular iron metabolism using pyridoxal isonicotinoyl hydrazone and other synthetic chelating agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03630260500455367

Unprecedented oxidation of a biologically active aroylhydrazone chelator catalysed by iron(III): serendipitous identification of diacylhydrazine ligands with high iron chelation efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03630260500455367

Development of potential iron chelators for the treatment of Friedreich's ataxia: ligands that mobilize mitochondrial iron

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03630260500455367

The effects of inhibition of heme synthesis on the intracellular localization of iron in rat reticulocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03630260500455367

PCTH: a novel orally active chelator of the aroylhydrazone class that induces iron excretion from mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03630260500455367

10.1080/03630260500455367

21 January 2018

Identifiers

DOI

1 reference

14 August 2017

1 reference